Serum Institute and Bharat Biotech Covid19 vaccines get CDSCO approval; Phase-III trials permit to Cadila
January 02, 2021
New Delhi: The Subject Expert Committee of CDSCO met on 1st and 2nd January, 2021 and made the following recommendations for the consideration and final decision of the Drugs Controller General of India :-
1) Grant of permission for restricted emergency use of vaccine, subject to multiple regulatory conditionalities, to M/s Serum Institute of India, Pune.
2) Grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, specially in the context of infection by mutant strains, to M/s Bharat Biotech International Ltd., Hyderabad.
3) Grant of permission for conduct of Phase-III Clinical Trial Protocol to M/s Cadila Healthcare Ltd, Ahmedabad
Related Stories
Indigenously developed DNA Vaccine Candidate by Zydus Cadila, approved for Phase III trials
Covid19 vaccine approval to Serum Institute and Bharat Biotech
Recent Stories
- Jamsaheb calls for Rajput unity; Asks to ensure defeat
- Large quantity of substandard oil being sold under branded label seized in Valsad
- Bomb threat at VR Mall in Surat; public evacuated, probe on
- With tears in eyes, Police Inspector tenders apology in Surat Court
- Rajkot Royal Mandhatasinh Jadeja comes in support of Rupala
- Viral video of two-year old child driving a bike; Police nab accused Taufik
- Atal bridge, walkways of Riverfront to remain open till 11 pm